Topics
January/February 2012 | pennsylvania Avenue Updates
The –25 Modifier: When and Why?
GEORGE A. WILLIAMS, MD
August 6, 2026
Norlase Expands European Footprint
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals
August 5, 2026
Vantage Biosciences Completes Enrollment in Phase 2 SeeClear Trial of Oral NPDR Therapy
August 4, 2026
University of Iowa Research Underpins First-in-Human UK Study of Gene Therapy Targeting Rare IRD
July/August 2026 Insert
Editorially independent supported by Abbvie and Regenxbio
July/August 2026 Supplement
Editorially Independent Content, Supported With Advertising From Astellas and ZEISS
July 2026 Supplement
Free Print Subscription
Email Newsletter
Conference Calendar
_1784132761.jpg?auto=compress,format&w=70)
